A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)

A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

NCT02130362 ·Status: ACTIVE_NOT_RECRUITING

Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

NCT00409617 ·Status: COMPLETED ·Phase: PHASE3

Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease

NCT00195715 ·Status: COMPLETED ·Phase: PHASE3

Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

NCT00105300 ·Status: COMPLETED ·Phase: PHASE3

Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)

NCT00427921 ·Status: COMPLETED ·Phase: PHASE3

Remission in Subjects With Crohn's Disease, 1 Year Phase

NCT00055497 ·Status: COMPLETED ·Phase: PHASE3

Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)

NCT01960790 ·Status: COMPLETED

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

NCT01298648 ·Status: COMPLETED

Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806

NCT00686374 ·Status: COMPLETED ·Phase: PHASE3

Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

NCT00077779 ·Status: COMPLETED ·Phase: PHASE3

A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

NCT00055523 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease

NCT00409682 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease

NCT02499783 ·Status: COMPLETED ·Phase: PHASE3

Interest of the Dosage of Adalimumab Serum Levels in Crohn's Disease Patients for Prevention of Postoperative Recurrence

NCT04200547 ·Status: TERMINATED ·Phase: NA

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

NCT02065570 ·Status: COMPLETED ·Phase: PHASE3

Special Investigation in Patients With Ulcerative Colitis

NCT01947816 ·Status: COMPLETED

Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis

NCT00573794 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease

NCT02015793 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease

NCT01235689 ·Status: COMPLETED ·Phase: PHASE3

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

NCT04524611 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05995353 ·Status: RECRUITING ·Phase: PHASE3

Remission in Subjects With Crohn's Disease, Open Label Extension

NCT01070303 ·Status: COMPLETED ·Phase: PHASE3

Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease

NCT00325078 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study

NCT02450513 ·Status: COMPLETED

Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

NCT00338650 ·Status: COMPLETED ·Phase: PHASE3